32 matches for your search in the start-up spotlight
rss
Danish biotech replaces cell-based methods with revolutionary cell-free technology, making gene therapy more accessible
28-Feb-2025
Gene therapy's biggest obstacle isn't science - it's manufacturing. While the field races forward with breakthrough treatments, production remains stuck in the 1980s, relying on unpredictable cell-based methods that make therapies costly and slow to develop. Today, Fuse Vectors announces $5.2 ...
With nearly 1,500 entities, Europe hosts a larger number of cancer-related startups than the US
04-Feb-2025
Cancer remains a major health threat in Europe, which accounts for nearly 25% of global cases and over 20% of deaths, despite having less than 10% of the world's population[1]. Technological advancements are improving survival rates, with European healthcare systems showcasing excellence in ...
One of the largest private Italian Biotech company financings to date
01-Oct-2024
Genespire, a biotechnology company developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases, announced the closing of a €46.6 million (~$52 million) Series B financing, co-led by Sofinnova Partners, XGEN Venture and CDP Venture Capital through its Large Venture ...
Award-winning technology combines a bioreactor and a centrifuge into one single vessel for the first time
23-May-2024
Over the last decade, several breakthrough Cell and Gene Therapy products have been approved in the USA and Europe to turn stem cells and immune cells into ‘living cures’, bringing hope to millions living with life-threatening conditions. However, these treatments remain out of reach for 98% of ...
“MIP Discovery’s synthetic affinity reagents hold huge potential to overcome bottlenecks in cell and gene therapy development and production”
28-Feb-2024
MIP Discovery, an innovative developer of non-biological affinity reagents designed to accelerate the development and production of cell and gene therapies, announced it has closed a £7 million GBP (~$9 million USD) Series A financing round, led by Mercia Ventures. Existing investor Calculus ...
Start-ups presented their ideas at the “Munich Demo Day” of the BioTech Bootcamp of BioM and SmiLe
12-Dec-2023
As part of this year's BioTech Bootcamp ofBioM Biotech Cluster Development GmbH and the life science business incubator„SmiLe Incubator“ from Lund, Sweden, the international, eight-week training program for prospective founders and young companies climaxed in the Munich “Demo Week”. Nine teams, ...
04-Sep-2023
AaviGen GmbH, a preclinical stage biotechnology company focused on the development of curative gene therapies for cardiovascular and cardiopulmonary diseases, announced the completion of its 17M € Series B financing round. Building on AaviGen’s proprietary portfolio of engineered cardiac-specific ...
"EG110A is the first genuinely innovative approach to be developed for patients suffering neurogenic bladder overactivity in more than a decade"
26-Jul-2023
EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions, announces the final closing of a Series A financing. EG 427 raised an additional €5 million in the final closing from a combination of existing investors and new family office investors, bringing the total ...
Astraveus raises €16.5 Million Series Seed round
03-Jul-2023
Astraveus SAS, the creator of modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing, exited stealth with the completion of an oversubscribed €16.5 million Series Seed financing led by AdBio partners, co-syndicated with M Ventures, Johnson & Johnson ...
Ikarovec is developing novel gene therapies to treat serious, but common eye diseases
06-Jun-2023
Rentschler Biopharma SE and Ikarovec, which is developing novel multicistronic gene therapies to treat major ophthalmic indications, announced that the two companies have entered into a collaboration. Under the agreement, Rentschler Biopharma’s ATMP site in Stevenage, UK, will support the ...
